ORYZON.jpg
ORYZON Reports Financial Results and Corporate Update for the 4th Quarter and Year Ended December 31, 2018
February 15, 2019 11:41 ET | Oryzon Genomics
-$0.04/share for the 12 months ended December 31st MADRID, Spain and CAMBRIDGE, Mass., Feb. 15, 2019 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a public...
ORYZON.jpg
ORYZON Announces Publication of a relevant paper for the therapeutic development of Iadademstat (ORY-1001) in Small Cell Lung Cancer (SCLC)
February 06, 2019 08:00 ET | Oryzon Genomics
Complete and durable tumor regression occurred with Iadademstat–induced NOTCH activation in a chemoresistant PDX model Further supports LSD1 inhibitors as a possible new and targeted therapy for SCLC...
ORYZON.jpg
Oryzon to present at upcoming international conferences
January 29, 2019 08:00 ET | Oryzon Genomics
21st Annual BIO CEO & Investor Conference 2019 in New York, USA12th Annual European Life Sciences CEO Forum in Zurich, Switzerland2019 BioCapital Europe in Amsterdam, The Netherlands31st Annual...
ORYZON.jpg
Oryzon to join the IBEX Small Cap Index
December 17, 2018 12:32 ET | Oryzon Genomics
The inclusion will become effective on December 24th MADRID, Spain and CAMBRIDGE, Mass., Dec. 17, 2018 (GLOBE NEWSWIRE) -- Oryzon Genomics (ISIN Code: ES0167733015, ORY), a public clinical-stage...
ORYZON.jpg
ORYZON Reports Financial Results and Corporate Update for the 3rd Quarter Ended September 30, 2018
November 02, 2018 08:00 ET | Oryzon Genomics
-$0.01/share for the 9 months ended September 30th MADRID, Spain and CAMBRIDGE, Mass., Nov. 02, 2018 (GLOBE NEWSWIRE) -- Oryzon Genomics (ISIN Code: ES0167733015, ORY), a public clinical-stage...
ORYZON.jpg
ORYZON receives approval to start CLEPSIDRA: a Phase IIa clinical trial in Small Cell Lung Cancer with Iadademstat (ORY-1001)
October 17, 2018 08:00 ET | Oryzon Genomics
The study will be done in SCLC patients in combination with Platinum-Etoposide chemotherapy MADRID, Spain and CAMBRIDGE, Mass., Oct. 17, 2018 (GLOBE NEWSWIRE) -- Oryzon Genomics S.A. (ISIN Code:...
ORYZON.jpg
Oryzon announces first patient enrolled in REIMAGINE: a Phase IIa clinical trial with Vafidemstat (ORY-2001) in aggressiveness
October 09, 2018 08:00 ET | Oryzon Genomics
MADRID, Spain and CAMBRIDGE, Mass., Oct. 09, 2018 (GLOBE NEWSWIRE) -- Oryzon Genomics S.A. (ISIN Code: ES0167733015, ORY), (“Oryzon”), a public clinical-stage biopharmaceutical company leveraging...
ORYZON.jpg
September 21st: World Alzheimer’s Day around the world
September 21, 2018 08:00 ET | Oryzon Genomics
Working together to raise awareness and challenge the stigmaWith a concerted effort, science will prevail Oryzon has two ongoing clinical trials in AD with Vafidemstat MADRID, Spain and CAMBRIDGE,...
ORYZON.jpg
ORYZON receives approval to start ALICE: a Phase IIa clinical trial in AML with Iadademstat (ORY-1001)
September 11, 2018 08:00 ET | Oryzon Genomics
The study will be done in elderly Acute Myeloid Leukemia (AML) patients not eligible for intensive chemotherapyIt is the first Phase II study of Iadademstat (ORY-1001) in combination therapy MADRID,...
ORYZON.jpg
Oryzon receives approval to begin REIMAGINE: a Phase IIa clinical trial with Vafidemstat (ORY-2001) in aggressiveness
September 07, 2018 08:40 ET | Oryzon Genomics
The approval has been granted by the Spanish Medicines AgencyThe study will be done in patients with 3 psychiatric disorders and 2 neurodegenerative disordersThis is the first Phase IIa study with...